Irvine Jennifer C, Favaloro Joanne L, Kemp-Harper Barbara K
Department of Pharmacology, Monash University, Clayton Victoria 3800, Australia.
Hypertension. 2003 Jun;41(6):1301-7. doi: 10.1161/01.HYP.0000072010.54901.DE. Epub 2003 May 12.
Nitric oxide (NO) plays an important role in the control of vascular tone. Traditionally, its vasorelaxant activity has been attributed to the free radical form of NO (NO*), yet the reduced form of NO (NO-) is also produced endogenously and is a potent vasodilator of large conduit arteries. The effects of NO- in the resistance vasculature remain unknown. This study examines the activity of NO- in rat small isolated mesenteric resistance-like arteries and characterizes its mechanism(s) of action. With the use of standard myographic techniques, the vasorelaxant properties of NO* (NO gas solution), NO- (Angeli's salt), and the NO donor sodium nitroprusside were compared. Relaxation responses to Angeli's salt (pEC50=7.51+/-0.13, Rmax=95.5+/-1.5%) were unchanged in the presence of carboxy-PTIO (NO* scavenger) but those to NO* and sodium nitroprusside were inhibited. l-Cysteine (NO- scavenger) decreased the sensitivity to Angeli's salt (P<0.01) and sodium nitroprusside (P<0.01) but not to NO*. The soluble guanylate cyclase inhibitor ODQ (3 and 10 micromol/L) concentration-dependently inhibited relaxation responses to Angeli's salt (41.0+/-6.0% versus control 93.4+/-1.9% at 10 micromol/L). The voltage-dependent K+ channel inhibitor 4-aminopyridine (1 mmol/L) caused a 9-fold (P<0.01) decrease in sensitivity to Angeli's salt, whereas glibenclamide, iberiotoxin, charybdotoxin, and apamin were without effect. In combination, ODQ and 4-aminopyridine abolished the response to Angeli's salt. In conclusion, NO- functions as a potent vasodilator of resistance arteries, mediating its response independently of NO* and through the activation of soluble guanylate cyclase and voltage-dependent K+ channels. NO- donors may represent a novel class of nitrovasodilator relevant for the treatment of cardiovascular disorders such as angina.
一氧化氮(NO)在血管张力的调控中发挥着重要作用。传统上,其血管舒张活性被归因于NO的自由基形式(NO*),然而NO的还原形式(NO-)也在体内产生,并且是大的输送动脉的强效血管扩张剂。NO-在阻力血管系统中的作用尚不清楚。本研究检测了NO-在大鼠离体小肠系膜类阻力动脉中的活性,并对其作用机制进行了表征。使用标准的肌动描记技术,比较了NO*(NO气体溶液)、NO-(安吉利盐)和NO供体硝普钠的血管舒张特性。在存在羧基-PTIO(NO清除剂)的情况下,对安吉利盐的舒张反应(pEC50 = 7.51±0.13,Rmax = 95.5±1.5%)未改变,但对NO和硝普钠的反应受到抑制。L-半胱氨酸(NO-清除剂)降低了对安吉利盐(P<0.01)和硝普钠(P<0.01)的敏感性,但对NO没有影响。可溶性鸟苷酸环化酶抑制剂ODQ(3和10 μmol/L)浓度依赖性地抑制了对安吉利盐的舒张反应(10 μmol/L时为41.0±6.0%,而对照组为93.4±1.9%)。电压依赖性钾通道抑制剂4-氨基吡啶(1 mmol/L)使对安吉利盐的敏感性降低了9倍(P<0.01),而格列本脲、iberiotoxin、蝎毒素和阿帕明则无作用。ODQ和4-氨基吡啶联合使用消除了对安吉利盐的反应。总之,NO-作为阻力动脉的强效血管扩张剂发挥作用,其反应独立于NO,通过可溶性鸟苷酸环化酶和电压依赖性钾通道的激活介导。NO-供体可能代表一类新型的硝基血管扩张剂,与治疗心血管疾病如心绞痛相关。